# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-Proof of Concept Study in Rapid Acting GLP-1 to commence in October 2024 with data expected in November 2024-Pre-clinical stud...
Modular Medical shares are trading higher Thursday after the company announced it has received U. S. Food and Drug Administrati...
Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology...
MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetesDesigned to be simpler and more affordable to expand access...
Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), a development-stage, insulin delivery technology company seeki...